breaking / AI

🚨 Isomorphic Labs Just Raised $5 Billion to Design Drugs With AI, Six Months After Its Last $2.1 Billion

Isomorphic Labs raised a $5bn Series C led by Greenoaks and Sequoia, six months after its $2.1bn Series B, to push AI-designed drugs to trials.

Isomorphic Labs Just Raised $5 Billion to Design Drugs With AI, Six Months After Its Last $2.1 Billion — Tech Arcade
Photo: ThisisEngineering / Unsplash

Isomorphic Labs has just raised $5 billion, the AI drug-discovery company spun out of Google DeepMind announced on Tuesday 17 November (Isomorphic Labs).

It is a Series C, it was oversubscribed, and it lands barely six months after the company’s $2.1 billion Series B in May (Bloomberg). That is $7.1 billion in one calendar year for a company that has not yet put a drug into a human.

⚡ What Happened

  • Greenoaks and Sequoia Capital co-led the round, joined by Andreessen Horowitz and several other new investors (Isomorphic Labs).
  • Alphabet kept writing big cheques, and every existing investor came back: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
  • The company did not disclose a valuation. Bloomberg reported earlier this month that the round would value it at about $50 billion; Isomorphic has not confirmed that figure (TNW).

The London company is run by Sir Demis Hassabis, the Nobel-winning co-creator of AlphaFold, with Max Jaderberg as president.

“Our drug design engine is generating molecules with unprecedented precision and speed.” — Demis Hassabis, founder and CEO, in the company’s announcement

🧠 Why It Matters

Isomorphic’s pitch is that its engine, IsoDDE, can design drug candidates faster than a traditional lab. The company says its internal oncology and immunology programmes, plus partnered ones, are showing positive preclinical results that set the stage for clinical entry (PR Newswire release).

Hassabis told Bloomberg the aim is “a platform to do hundreds of drugs a year” (TNW). For comparison, the entire industry gets a few dozen new drugs approved by the US FDA in a typical year.

The money goes on scaling IsoDDE, expanding the pipeline into new biology (including beyond small molecules), and building the clinical development machinery to move candidates into trials. In other words: the hard, slow, expensive part.

It also tells you where investor money is flowing during a rough week for AI stocks. Chips are wobbling. AI for biology just got one of the biggest private cheques of the year.

🔜 What To Watch

  • First human trials. Hassabis said in January he expected the first clinical trials by the end of 2026. He gave Bloomberg no updated timeline, and there are six weeks left.
  • Partner deals. Eli Lilly and Novartis are already partners. Fresh pharma deals would be the clearest sign the engine is worth what investors are paying.
  • The valuation. If the reported ~$50 billion holds, Isomorphic would be valued like a large listed pharma company before it has a single drug in the clinic.

Some details, including the valuation, are still emerging.


Sources

❓ Quick answers

How much did Isomorphic Labs raise in its Series C?

$5 billion, announced on 17 November 2026, co-led by Greenoaks and Sequoia Capital, according to Isomorphic Labs.

What is Isomorphic Labs valued at?

The company did not disclose a valuation. Bloomberg reported earlier in November 2026 that the round would value it at about $50 billion, which Isomorphic has not confirmed.

Who runs Isomorphic Labs and what does it do?

Isomorphic Labs is a London AI drug-discovery company spun out of Google DeepMind, led by CEO Sir Demis Hassabis. It uses its IsoDDE engine to design drug candidates, with oncology and immunology programmes in preclinical development.